Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + ixazomib + dexamethasone as second-line therapy in lenalidomide-pretreated multiple myeloma
2018-002282-19Phase 2Completed
- Sponsor
- Hellenic Society of Hematology
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, ixazomib and dexamethasone in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Overall response rate. Started Aug 2018; status: completed.
02
Drugs
daratumumabixazomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-002282-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002282-19.